Susquehanna International Group’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Susquehanna International Group’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-208,100	Closed	-$22.3M	–	13612
2023 Q1	$22.3M	Sell	208,100 -268,300	-56%	-$30.9M	﹤0.01%	1600
2022 Q4	$52.4M	Buy	476,400 +382,500	+407%	+$24.8M	0.01%	857
2022 Q3	$5.54M	Buy	93,900 +78,800	+522%	+$3.61M	﹤0.01%	2998
2022 Q2	$426K	Sell	15,100 -71,500	-83%	-$2.07M	﹤0.01%	8663
2022 Q1	$3.27M	Buy	86,600 +7,300	+9%	+$289K	﹤0.01%	4460
2021 Q4	$3.14M	Buy	+79,300	New	+$2.48M	﹤0.01%	4572

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Susquehanna International Group's RXDX Position: Q2 2023 in Review

Susquehanna International Group sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 50,128 shares — an estimated $5.38M sold.

Susquehanna International Group first reported a position in RXDX in Q1 2022 and held it in 5 quarters. The position peaked at $5.38M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Susquehanna International Group reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Susquehanna International Group sold 50,128 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $5.38M.
Susquehanna International Group first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2022 and held it in 5 quarters.
Susquehanna International Group's Prometheus Biosciences, Inc. Common Stock position peaked at $5.38M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Susquehanna International Group's 13F filing for Q2 2023, filed 11 Aug 2023.